Introduction
TNBC, triple-negative, breast cancer
BREAST CANCER
Neoadjuvant chemotherapy (NAC) is widely used to cure breast cancer (BC), for both local control and for the eradication of micrometastases. In particular, it is essential for treating both human epidermal growth factor receptor 2 (HER2)-positive BC and triple-negative BC (TNBC) [The addition of trastuzumab (T-mab), lapatinib, and their combination to paclitaxel showed a 29.5, 24.7, and 51.3% pCR rates, respectively [At present, there are three clinically available taxanes. Albumin-bound paclitaxel (nab-PTX; Abraxane